 1 
 
Johnson & Johnson Pharmaceutical Research & Development 
 
Millennium Pharmaceuticals, Inc.
 
Statistical Analysis Plan
 
A Randomised, Open-Label, Multicentre Phase 3 Study of the Combination of 
Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone  
(VcR-CAP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and 
Prednisone (R-CHOP) in Patients With Newly Diagnosed Mantle Cell Lymphoma 
who are not Eligible for a Bone Marrow Transplant  
 
Protocol 26866138-LYM-3002; Phase 3
 
JNJ-26866138 (VELCADE* [Bortezomib] for Injection) 
 
 * VELCADE is the exclusive trademark of Millennium Pharmaceuticals, Inc., registered in the United States and internationally. 
Issue/Report Date:  8 January 2014 
Prepared by: Janssen Research & Development, LLC  
Document No.:  EDMS-ERI-28105966:2.0 
 
Compliance: The study described in this report was performed acco rding to the principles of Good Clinical Practice 
(GCP). 
Confidentiality Statement 
The information in this document contains trade secrets and commercial information that are privileged or confidential 
and may not be disclosed unless such disc losure is required by applicable law or regulations. In any event, persons to 
whom the information is disclosed must be informed that th e information is privileged or  confidential and may not be 
further disclosed by them. These restric tions on disclosure will apply equally to all future information supplied to you 
that is indicated as privileged or confidential. 
JNJ-26866138 (VELCADE* [Bortezomib] for Injection) Statistical Analysis Plan LYM-3002 
 2TABLE OF CONTENTS 
1. INTRODUCTION .......................................................................................................... 4  
1.1. Trial Obje ctives ............................................................................................................. 4 
1.2. Study Design ................................................................................................................ 4  
1.3. Statistical Hypotheses for Trial Obje ctives ................................................................... 6  
1.4. Sample Size Justification .............................................................................................. 7 
1.5. Randomization and Blinding ......................................................................................... 7  
2. GENERAL ANALYSIS DEFINITI ONS ......................................................................... 8  
2.1. Imputation of Mi ssing Data ........................................................................................... 8  
2.1.1. Missing/Partial Dates in Screening Visit ....................................................... 8  
2.1.2. Missing/Partial Dates in Ad verse Events/Concomitant 
Therapies/Subsequent Therapies ................................................................ 8  
2.1.3. Missing/Partial Date s in Death ..................................................................... 9  
2.2. Analysis Sets .............................................................................................................. 10  
2.2.1. Efficacy Analysis Set(s) .............................................................................. 10  
2.2.1.1. Primary Efficacy Analysis Set ................................................................. 10  
2.2.1.2. Secondary Efficacy Analysis Set ............................................................ 10  
2.2.1.2.1.  Per-Protocol Analysis Set ....................................................................... 10  
2.2.1.2.2.  Response Evaluabl e Populat ion ............................................................. 10  
2.2.1.2.3.  Biomarker P opulation .............................................................................. 10  
2.2.2. Safety Analysis Set .................................................................................... 10  
2.3. Definition of Subgroups .............................................................................................. 10  
2.4. Other General De finitions ........................................................................................... 11  
2.4.1. Treatment Groups ...................................................................................... 11  
2.4.2. Individual Study Start (Day 1), Study Day and Month ................................ 12  
2.4.3. End of Follow-up and Length of Follow-up ................................................ 12  
2.4.4. Treatment Start, Treatment End, and Time on Study Treatment .............. 12  
2.4.5. Number of Treatm ent Cycles ..................................................................... 13  
2.4.6. Properties of Treat ment Cycles .................................................................. 13  
2.4.7. Dose Intensity and Relati ve Dose Intensity ............................................... 14  
2.4.8. Age and Age Cate gories ............................................................................ 15  
2.4.9. Baseline Values .......................................................................................... 15 
2.4.10. Categories of Extranodal Sites of Di sease ................................................ 15  
2.4.11. Category of International Prognosis Index (IPI) ......................................... 15  
2.4.12. Stage of MCL at  Diagnosi s ........................................................................ 16  
2.4.13. Creatinine Clearance and Its Cate gory ...................................................... 16  
2.4.14. Time since Init ial Diagno sis ........................................................................ 16  
2.4.15. Relationship of Adverse Event s to Study Medication ................................ 16  
2.4.16. Study Medication-Re lated Death ............................................................... 17  
2.4.17. Dose Discontinuation of A Specific Study Drug Due to Adverse Events ... 17  
2.4.18. Adverse Events Leading to Treatment Discontinuation, and Study 
Medication-Related Treatm ent Disconti nuation ......................................... 17  
2.4.19. Linking of Adve rse Event s .......................................................................... 17  
2.4.20. Concomitant Medication During Treat ment ............................................... 18  
2.4.21. Categories of Body Surface Area ............................................................... 18 
2.4.22. Censoring Reason s for PFS ...................................................................... 18  
2.4.23. Censoring Reasons for Overall Surv ival .................................................... 19  
3. INTERIM ANALYSIS AND DATA MONI TORING COMMITTEE REVIEW ............... 19  
4. SUBJECT INFORMATION ........................................................................................ 20  
4.1. Demographics and Baseline Characteristics .............................................................. 20  
4.2. Disposition Information ............................................................................................... 21  
4.3. Extent of Exposure ..................................................................................................... 22  
4.4. Protocol Devi ations  ..................................................................................................... 22  
JNJ-26866138 (VELCADE* [Bortezomib] for Injection) Statistical Analysis Plan LYM-3002 
 34.5. Concomitant Medications ........................................................................................... 22  
4.6. Subsequent Therapi es for MCL.................................................................................. 23  
5. EFFICACY  .................................................................................................................. 23  
5.1. Analysis Specifications ............................................................................................... 23  
5.1.1. Level of Significance .................................................................................. 23  
5.1.2. Data Handlin g Rules .................................................................................. 23  
5.1.3. Definitions for Some E fficacy Variables ..................................................... 24  
5.1.3.1. Tumor Assessment by Independent Radiology Review Committee 
(IRC) ........................................................................................................ 24  
5.1.3.2. Date of Progression ................................................................................ 24  
5.1.3.3. Complete Response  Assessment ........................................................... 25  
5.1.3.4. Tumor Assessment by  Investigator......................................................... 25  
5.1.3.5. Best Overall Response ........................................................................... 25  
5.2. Primary Efficacy  Endpoint(s) ...................................................................................... 25  
5.2.1. Definiti on .................................................................................................... 25  
5.2.2. Analysis Methods ....................................................................................... 26  
5.3. Major Secondary Endpoints ....................................................................................... 27  
5.3.1. Definiti on .................................................................................................... 27  
5.3.2. Analysis Methods ....................................................................................... 29  
5.4. Other Efficacy Variables ............................................................................................. 30  
5.4.1. Definiti on .................................................................................................... 30  
5.4.2. Analysis Methods ....................................................................................... 30  
6. SAFETY ...................................................................................................................... 31 
6.1. Adverse Ev ents .......................................................................................................... 31  
6.1.1. All Adverse Events ..................................................................................... 31  
6.1.2. Adverse Events of Clin ical Interest ............................................................ 33  
6.1.2.1. Peripheral Neur opathies ......................................................................... 33  
6.1.2.2. Cardiac Rhythm and Conduc tion Abnormalities ..................................... 34  
6.1.2.3. Heart Failure ........................................................................................... 34  
6.1.2.4. Pericardial Disease ................................................................................. 35  
6.1.2.5. Acute Diffuse Infiltrative  Pulmonary Disease .......................................... 35  
6.1.2.6. Reactivation of Hepatitis  B ...................................................................... 35  
6.1.2.7. Acute Hypersens itivity ............................................................................. 36  
6.1.2.8. Central Nervous System Disorders ......................................................... 36  
6.1.2.9. Herpes Zoster Infection ........................................................................... 36  
6.1.2.10. Thrombocytopenic Bleeding Events ....................................................... 37  
6.1.2.11. Neutropenic Sepsis and Infections Events ............................................. 38  
6.1.3. Death .......................................................................................................... 38  
6.2. Clinical Laborat ory Tests ............................................................................................ 39  
6.3. Vital Signs and Physical Examination Findings .......................................................... 39  
6.4. Electrocardiogram and ECHO/MUGA Scans ............................................................. 40  
7. PATIENT-REPORTED OUTCOM ES (PRO) ENDP OINTS ........................................ 40  
7.1. Definition .................................................................................................................... . 40 
7.2. Analysis Methods ....................................................................................................... 40  
8. BIOMARKER EVALUATIONS ................................................................................... 42 
8.1. Definition .................................................................................................................... . 42 
8.2. Analysis Methods ....................................................................................................... 42  
REFERE NCES .................................................................................................................... .... 43 
ATTACHMENT .................................................................................................................... .... 44 
 
  
JNJ-26866138 (VELCADE* [Bortezomib] for Injection) Statistical Analysis Plan LYM-3002 
 4 
1. INTRODUCTION 
This statistical analysis plan (SAP) contains definitions of analysis sets, derived variables 
and statistical methods for the an alysis of efficacy and safety.  
1.1. Trial Objectives 
Primary Objective 
To determine which regimen of chemot herapy rituximab, cyclophosphamide, doxorubicin, 
VELCADE, and prednisone  (VcR-CAP) or  rituximab, cyclophosphamide, doxorubicin, 
vincristine, and prednisone (R-CHOP) provides greater benefit in newly diagnosed mantle 
cell lymphoma (MCL) subjects with Stage II, III, or IV disease, as assessed by significant 
prolongation of progression-free survival (PFS). 
Secondary Objectives 
The secondary objectives are: 
 To determine time to progression (TTP) 
 To determine the duration of response (DoR), time to next treatment (TNT), and 
treatment-free interval  
 To determine overall response (complete response [CR]+CR unconfirmed [CRu]+partial response [PR]) and CR rates (CR+CRu) 
 To determine overall survival (OS) 
 To determine the 18-month survival rate 
 To evaluate the safety of VcR-CAP compared to R-CHOP 
Exploratory Objectives 
 To evaluate patient-reported outcomes (PROs) utilizing the European Organisation for 
Research and Treatment of Cancer quality of life ques tionnaire (EORTC-QLQ-C30), 
EQ-5D, and Brief Fatigue Inventory (BFI) instruments 
 To evaluate medical resource utilization (MRU) information which may be used in 
future economic evaluation models 
 To identify subject populations that are more  or less likely to respond to VcR-CAP or 
R-CHOP through the evaluation of biomarker analyses 
 
1.2. Study Design 
This is a randomized, open-label, multicente r, prospective study to compare the efficacy 
and safety of the combination of VcR-CAP to that of R-CHOP in su bjects who have newly 
diagnosed MCL and who are ineligible  for bone marrow transplantation. 
JNJ-26866138 (VELCADE* [Bortezomib] for Injection) Statistical Analysis Plan LYM-3002 
 5At least 486 subjects will be randomized into 1 of 2 arms (Treatment  Arm A or Treatment 
Arm B) in a 1:1 ratio taking into account the fo llowing stratification f actors: International 
Prognostic Index (IPI) and stag e of disease at diagnosis. 
Treatment Arm A (VcR-CAP): rituximab 375 mg/m2 intravenous (IV) on Day 1, 
cyclophosphamide 750 mg/m2 IV on Day 1, doxorubicin 50 mg/m2 IV on Day 1, 
VELCADE 1.3 mg/m2 IV on Days 1, 4, 8 and 11, and prednisone 100 mg/m2 per os (PO) 
on Day 1 to Day 5 of a 21-day (3-week) cycle for 6 cycles (or 8 cycles if a response is first 
documented at the Cycle 6 assessment). 
Treatment Arm B (R-CHOP): rituximab 375 mg/m2 IV on Day 1, cyclophosphamide 
750 mg/m2 IV on Day 1, doxorubicin 50 mg/m2 IV on Day 1, vincristine 1.4 mg/m2 
(maximum total of 2 mg) IV on Day 1, and prednisone 100  mg/m2 PO on Day 1 to Day 5 
of a 21-day (3-week) cycle for 6 cycles (or 8 cycl es if a response is first documented at the 
Cycle 6 assessment). 
The study will include a Screening Phase, a Treatment Phase, a Short-term Follow-up 
Phase, and a Long-term Follow-up Phase. The Screening Phase will be up to 28 days 
(56 days for bone marrow evaluation) prior to randomization. The Treatment Phase will 
extend from randomization until 6 cycles of tr eatment have been given (or 2 cycles beyond 
a response documented in Cycle 6). The Shor t-term Follow-up Phase will extend from the 
End-of-Treatment Phase to progressive disease (PD; or relapse if subject achieves a CR or 
CRu), initiation of alternate antineoplastic th erapy, decision by the subject to completely 
withdraw from the study and refuse any furthe r study related procedure, or death. Subjects 
who are withdrawn from the study treatment due to adverse events, or reasons other than 
above and are willing to continue study follow-up procedures can be followed as per 
protocol for PD or death. 
The Long-term Follow-up Phase will be used to assess survival and will document when 
the subject has died.  Three interim analyses are planned for this study. The first interim analysis will occur after 
the first 100 subjects have been randomized into the study and will assess safety and the 
concordance rate of the dia gnosis of MCL when central review is compared with the 
investigator assessment of the diagnosis. Th e concordance rate of the diagnosis of MCL 
will also be reviewed in a b linded manner at 50% accrual. This may be used to recalculate 
the sample size to ensure an adequate numb er of PFS events (approximately 280) in those 
subjects with a centrally conf irmed MCL diagnosis at the tim e of the final analysis (295 
PFS events in total). A review of these data will occur by the IDMC. 
JNJ-26866138 (VELCADE* [Bortezomib] for Injection) Statistical Analysis Plan LYM-3002 
 6A second interim analysis for safety will occu r after 100 subjects in each arm (200 subjects 
in total) have either completed the study tr eatment or discontinue d the study treatment, 
which allows sufficient exposure for review of cumulative toxicity. 
The third interim analysis is pl anned after at least 148 events have occurred. If, at the time 
of the third interim analysis, the pre-specified  superiority boundaries for PFS are met, then 
the study will be terminated and superiority of the experimental arm (VcR-CAP) will be 
declared over the comparator arm (R-CHOP). If the pre-specified futility boundaries for 
PFS are met, then the study will be terminated due to futility. 
If pre-specified boundaries are no t met at the time of the thir d interim analysis, the final 
analysis of the study will occu r after 295 events have  been observed in the ITT population. 
An Independent Data Monitoring Committee (IDMC) has been commissioned for this 
study. 
1.3.  Statistical Hypotheses for Trial Objectives 
The primary statistical hypothesi s is that there is no differe nce between the two treatment 
groups (Treatment Group A: VcR-CAP, and Tr eatment Group B: R-CHOP) with regard to 
PFS. 
Secondary statistical hypotheses are as follows: 
1) There is no difference between the two treatment groups with respect to TTP 
2) There is no difference between the two tr eatment groups with respect to TNT; 
3) There is no difference between the two treatment groups with respect to the 
complete response (CR+CRu) rate; 
4) There is no difference between the two tr eatment groups with respect to OS;  
5) There is no difference between the two tr eatment groups with respect to overall 
response (CR+CRu+PR) rate (ORR); 
6) There is no difference between the two tr eatment groups with respect to 18-month 
survival rate. 
7) There is no difference between the two tr eatment groups with respect to treatment 
free interval 
JNJ-26866138 (VELCADE* [Bortezomib] for Injection) Statistical Analysis Plan LYM-3002 
 7Exploratory hypotheses include: 
There is no difference between the two tr eatment groups with respect to the PRO 
endpoints as defined in Section 7. 
There is no difference between the two treatment groups within each biomarker 
subgroup as defined in Section 8. 
Analysis of DoR will be descriptive instead of in ferential. This is due to the fact that the 
analyses can only be performed on subsets of  subjects determined by a post-randomization 
outcome.  
1.4. Sample Size Justification 
The sample size calculation for the study popula tion is based on the following assumptions. 
The median PFS of Treatment Arm B (R-CHOP)  is 18 months. Assuming that Treatment 
Arm A (VcR-CAP) can improve the median PFS by 40%, i.e. from 18 months to 25 
months, a total number of 295 events (PD or death) provides 80% pow er (alpha = 0.05, 
two-sided) to detect such improvement . Assuming a 24-month accrual and 18-month 
follow-up, 486 subjects in total are needed for the study (243/arm). 
1.5. Randomization and Blinding 
Subjects will be assigned in a 1:1 ratio to 1 of the 2 treatment groups based on a computer-
generated randomization schedule prepared by the sponsor before the study. The sponsor 
and the investigational sites will be b linded to all data reviewed by the IDMC. 
Permuted blocks central randomization will be  implemented in conducting this study. The 
randomization will be stratified by two stratific ation factors: IPI (0-1, 2, 3, and 4-5) and 
stage of disease at diagnosis (II, III, and IV) per the Amer ican Joint Committee on Cancer 
NHL staging system. The stratified randomization minimizes the imbalance in the 
distribution of treatment numbers within the levels of each individual stratification factors. 
The IPI is the total score of the following risk factors (score 1 for each positive factor):  age 
>60 years, MCL Stage III or IV at dia gnosis, Eastern Cooperative Oncology Group 
(ECOG) performance status score >1, >1 extranodal site involvement, and lactate 
dehydrogenase (LDH) above normal limits. For st ratification, the scores will then be 
categorized (low [0-1 factor], low-intermediate  [2 factors], high-intermediate [3 factors] 
and high [4-5 factors]). The stage of disease at diagnosis will also be used for stratification and will be assessed 
using the American Joint Committee on Cancer NHL staging system (see Attachment 11 
of Protocol 26866138LYM3002). 
JNJ-26866138 (VELCADE* [Bortezomib] for Injection) Statistical Analysis Plan LYM-3002 
 82. GENERAL ANALYSIS DEFINITIONS 
2.1. Imputation of  Missing Data 
Unless otherwise specified, no data imputation will be applied for missing values and all 
available data for all subjects will be presen ted. For PRO data, missing elements may be 
substituted with the average of non-missing ite ms per the published methods of analysis 
using well-established scali ng programs, and missing scores  will be handled using 
statistical techniques as outlined in the section for PRO data. 
2.1.1. Missing/Partial Da tes in Screening Visit 
The following rules apply to dates recorded in th e screening visits except for prior therapies 
(excluding prior systemic therapies for MCL). 
 If only the day-component is missing, the first day of the month will be used if the year 
and the month are the same as those for the first treatment. Otherwise, the 15th will be 
used unless it is later than the first treatment. 
 If only a year is present, and it is the same as the year of the first treatment, 15 January 
will be used unless it is later than the first treatment, in which case the date of 1 January will be used. 
 If only a year is present, and it is not the same  as the year of the first treatment, 15 June 
will be used, unless other data indicate that the date is earlier. For instance, the 
diagnosis date of MCL should be used to impute missing month/day of the start dates 
for prestudy systemic therapy for MCL if th e diagnosis date is later than 15 June. 
2.1.2. Missing/Partial Dates in Adverse Events/Concomitant 
Therapies/Subsequent Therapies 
Every effort will be made to avoid missing/par tial dates in on-study data. In case that the 
resolution date of a resolved adverse event, or the stop date of a concomitant therapy is 
missing, the following rules are to be used unless conflicting data  exists: if m onth and year 
are present and the day of the month is missi ng, the last day of the month is imputed. If 
only a year is present, 31 December will be us ed. After imputation, th e imputed dates will 
be compared against the date of death, if available. If the date is later than the date of death, 
the date of death will be used as the imputed date instead. 
In case that the onset date of an adverse event is missing completely or partially, the 
following imputation rules will be used. 
1) When month and year are present and the day of the month is missing, 
 If the onset month and year are the same as the month and year of first treatment 
with study drug, the day of first treatment or the day-component of the resolution 
date are imputed, whichever is earliest. 
JNJ-26866138 (VELCADE* [Bortezomib] for Injection) Statistical Analysis Plan LYM-3002 
 9 If the onset month and year are not the same  as the month and year of first treatment 
with study drug, the first day of the month is imputed. 
2) When only a year is present, or no co mponents of the onset date are present,  
 If the imputed resolution date is available, the later of the imputed resolution date 
(possibly imputed) and the date of first treatment will be used. 
 If the imputed resolution date  is missing, and the onset-year is the same as the year 
of first treatment with study drug, then the date of first treatment with study drug is 
used. 
 Otherwise if only a year is present, 1 January of that year is imputed.  
3) If none of the previous rule s can be applied, then the date of first treatment with study 
drug is imputed as the onset date. 
The imputation rules for missing/partial start dates of concomitant therapies will be the 
same as the above with the exception as follows. 
For prior therapy data recorded in the concomitant medication page, no imputation will be 
done for start dates. 
The imputation rules for missing/partial start dates of subsequent therapies will be the same 
as the above with the exception as follows. 
1) When month and year are present and the day of the month is missing, 
 If the month and year of th e start date are the same as the month and year of 
treatment termination, the day of treatmen t termination visit or the day-component 
of the stop date is imputed, whichever is earliest. 
 If the start month and year are not the sa me as the month and year of treatment 
termination visit, the first day of the month is imputed. 
2) When only a year is present, or no components of the start date are present, the date will 
not be imputed. 
2.1.3. Missing/Partial Dates in Death 
If month and year are present and the day of the month is mi ssing, the last day of the month 
is imputed.  
JNJ-26866138 (VELCADE* [Bortezomib] for Injection) Statistical Analysis Plan LYM-3002 
 102.2. Analysis Sets 
2.2.1. Efficacy Analysis Set(s) 2.2.1.1. Primary Efficacy Analysis Set 
The primary efficacy analysis set is the inte nt-to-treat (ITT) populat ion, which includes all 
randomized subjects. 
2.2.1.2. Secondary Efficacy Analysis Set 
2.2.1.2.1. Per-Protocol Analysis Set 
The per-protocol (PP) population is defined as all subjects who are randomized to treatment 
who meet all inclusion and ex clusion criteria, who received at least 1 dose of study drug, 
and undergo at least one post-ba seline disease assessment (pos t-baseline tumor assessment 
by independent radiology reviewers [IRC]). Subjects in this population will be analyzed 
according to the treatment to which they were randomized. The analyses using the PP 
population will be considered  as sensitivity analyses. 
2.2.1.2.2. Response Evaluable Population 
The response-evaluable population is defined as all subjects in the ITT population who 
receive at least 1 dose of study drug, have at least 1 measurable tumor mass (greater than 
1.5 cm in the longest dimension and greater than  1.0 cm in the short axis) at baseline, and 
have at least 1 post-baseline tumor assessme nt by IRC, before any subsequent anti-
lymphoma treatment. 
2.2.1.2.3. Biomarker Population 
The biomarker population is defined as subj ects who are randomized to treatment (ITT), 
whose biomaterial is available,  who have consented to partic ipate in the study’s biomarker 
and pharmacogenomic evaluations or future re search, and have biomarker data generated 
for the biomarker evaluation.  
2.2.2. Safety Analysis Set 
The safety population, which includes all randomi zed subjects who receive at least 1 dose 
of study drug, will be used in the safety analyses.  
2.3. Definition of Subgroups 
In general, the following subgroup analyses are to be performed for efficacy and safety. 
Additional subgroup analyses will also be perfor med for selected efficacy and/or safety 
endpoints, which are descri bed in Sections 5 and 6. 
JNJ-26866138 (VELCADE* [Bortezomib] for Injection) Statistical Analysis Plan LYM-3002 
 11Subgroup Definition of Group Analysis 
Type 
IPI risk low [0-1 factor], low-intermediate [2 factors], high-
intermediate [3 factors], high [4-5 factors] E, S 
Sex Male, Female E, S 
Race White, Non-White E, S 
Region European Union, North America Region, Rest of World E, S 
Age 65, >65   E, S 
Stage of Disease at Diagnosis II, III, IV E, S 
LDH  Normal, Elevated E 
White Cell Count 
(WBC) <6.7, 6.7-<10, 10-<15, >=15 E 
ECOG 0: asymptomatic, 1: symptomatic, Fully Ambulatory, 2: 
symptomatic, in Bed<50% of the Day  E 
Renal Function 
(mL/min) Baseline creatinine clearance:  Renal impairment (<=60), 
Normal renal function (>60) S 
Liver Function Baseline ALT and AST<1.5*ULN, ALT/AST>=1.5*ULN S 
E= efficacy (primary, secondary endpoi nts); S= Safety (adverse events)  
 
In order to demonstrate applicability of study results to the US population, a 
US/Canada/Western Europe subset will be  created where Western Europe includes 
Austria, Belgium, France, Germany, Ital y, Portugal, and Spain. Summary data for 
demographics, baseline disease characteristic s, key efficacy endpoints (progression free 
survival by IRC and Investigator, progression free survival for US/Canada subset, time to 
tumor progression, overall survival, best overall response), and treatment-emergent 
adverse events will be generated for the US/Canada/Western Europe subset. 
2.4. Other General Definitions 
Unless specified otherwise, the dates used in the derivations ar e those obtained after 
applying the rules speci fied in Section 2.2. 
2.4.1. Treatment Groups There are two variables for treatment group identification (Treatme nt Group A: VcR-CAP 
or Treatment Group B: R-CHOP).  The first variable identifie s the treatment group to which 
a subject is randomized. All randomized subjec ts will have a nonmi ssing value for this 
variable. 
The second variable denotes the actual treatment recei ved. This variable is derived from 
the dosing data of the study medication. A subj ect is in the VcR-CA P group if the subject 
receives at least one dose of VELCADE; otherwise, the actu al treatment group is R-CHOP. 
Those subjects without any dose of th e study medications (VELCADE, rituximab, 
cyclophosphamide, doxorubicin, vincristine, or pr ednisone) will have this variable set as 
missing. 
JNJ-26866138 (VELCADE* [Bortezomib] for Injection) Statistical Analysis Plan LYM-3002 
 122.4.2. Individual Study Start (Day 1), Study Day and Month 
Individual Study Start (Day 1) is the day of randomization.  
Study day is equal to the date of procedure minus the date of randomization plus one.  
A month is defined as 365.25/12 days. 
2.4.3. End of Follow-up and Length of Follow-up 
The end of follow-up is either the date of d eath or the end of survival follow-up, defined 
as the maximum date of the following study evaluations: randomization, vital signs, ECOG 
performance status, CT scans (neck, chest, abdomen, and pelvis), dates of assessable 
lesions or new lesions, physical examinati on, bone marrow evaluations, labs (hematology, 
chemistry), study drug administration, subseque nt therapy, invest igator-assessed PD, 
relapse from CR/CRu, investigator determ ined response, and survival follow-up. 
Length of follow-up (in months) equals to the end of follow-up minus  study start, then 
divided by 365.25/12. 
2.4.4. Treatment Start, Treatment End, and Time on Study Treatment 
Treatment start is the date of first dose of  study medication (dose>0 for any of the study 
drugs: VELCADE, rituximab, cyclophospham ide, doxorubicin, vincristine, and 
prednisone). Treatment end is the date of th e last dose of the study medication (dose >0 for 
any of the six drugs: VELCADE, rituximab, cyclophosphamide, doxorubicin, vincristine, 
and prednisone).  Time (weeks) on study trea tment equals treatment end minus treatment 
start plus 1, then divided by 7. 
For subjects randomized to VcR-CAP, the star t date of VELCADE is the date of first 
nonzero dose of VELCADE, and the stop date of  VELCADE is the date of last nonzero 
dose of VELCADE. Time (in weeks) on VELC ADE equals the stop date minus the start 
date plus 1, then divided by 7. Note that time on VELCADE can only be determined for 
subjects who have received at least one dose of VELCADE. 
For subjects randomized to R-CHOP, the start date  of vincristine is th e date of first nonzero 
dose of vincristine, and the stop date of vinc ristine is the date of  last nonzero dose of 
vincristine. Time (in weeks) on vincristine equals the stop date minus the start date plus 1, 
then divided by 7. Note that ti me on vincristine can only be  determined for subjects who 
have received at least one dose of vincristine. 
The start date of rituximab is the date of first nonzero dose of rituximab, and the stop date 
of rituximab is the date of last nonzero dos e of rituximab. Time (in weeks) on rituximab 
equals the stop date minus the start date plus 1, then divided by 7. 
JNJ-26866138 (VELCADE* [Bortezomib] for Injection) Statistical Analysis Plan LYM-3002 
 13The start date of cyclophosphamide is the date of first nonzero dose of cyclophosphamide, 
and the stop date of cyclophosphomide is  the date of last nonzero dose of 
cyclophosphamide. Time (in weeks) on cyclophos phamide equals the stop date minus the 
start date plus 1, then divided by 7. 
The start date of doxorubicin is the date of  first nonzero dose of doxorubicin, and the stop 
date of doxorubicin is the date of last nonzero dose of doxorubicin. Time (in weeks) on 
doxorubicin equals the stop date minus the start date plus 1, then divided by 7. 
The start date of prednisone is the date of  first nonzero dose of prednisone, and the stop 
date of prednisone is the da te of last nonzero dose of pre dnisone. Time (in weeks) on 
prednisone equals the stop date minus the start date plus 1, then divided by 7. 
2.4.5. Number of Treatment Cycles 
The first treatment cycle is the first cycle in which a subject recei ves any nonzero dose of 
the study drugs (VELCADE, rituximab, cycl ophosphamide, doxorubicin, vincristine, and 
prednisone). The last treatment  cycle is the last cycle in  which a subject receives any 
nonzero dose of the study drugs. Number of treat ment cycles equals the last cycle number 
minus the first cycle number plus 1.  
For each of the study drugs (VELCADE , rituximab, cyclophosphamide, doxorubicin, 
vincristine, and prednisone), th e first (or last) treatment cycle on this drug is the first (or 
last) cycle in which a subject receives any nonzero dose of the study drug, and the number 
of cycles on this study drug equals the la st cycle minus the first cycle plus 1. 
Note that number of cycles on rituxi mab, cyclophosphamide, doxorubicin, or prednisone 
can be determined for all treated subjects,  while the number of cycles on VELCADE can 
only be determined for subjects randomized to receive VcR-CA P, and the number of cycles 
on vincristine can only be determined fo r subjects randomized to receive R-CHOP. 
2.4.6. Properties of Treatment Cycles 
For each treatment cycle, the following variables are to be derived.  
 Cycle delay ( 5 days)  to flag if this cycle is delaye d for at least 5 days (date of Day 
1 in the current cycle – date of Day 1 in the previous cycle is 26 days) and checked 
on the case report form (CRF) by i nvestigator as cycle delayed. 
 Reasons for cycle delay ( 5 days)  to record reasons for cycl e delay of at least 5 days 
as captured in CRF (AE or Other).  
 Cycle start  the date of the first dose of any of the study drugs (including zero doses). 
 Cycle stop  For cycles other than the last one, cy cle end is defined as the day before 
the start of the next cycle; for the last cycle, it is defined as  the visit date of the end of 
JNJ-26866138 (VELCADE* [Bortezomib] for Injection) Statistical Analysis Plan LYM-3002 
 14treatment visit (or the cycle start plus 20 days in case that the end of treatment visit is 
not performed yet). 
 Dose reduction  to flag if the dose of the study medication is reduced (each drug has 
its own flag[s]). For VELCADE, a dose is considered reduced if a nonzero dose is 
marked as reduced on the CRF and the prescr ibed dose is lower than the previous non-
zero dose level. For rituximab, a nonzero dose is considered as reduced if it is >25% 
lower than the prescribed dose. For other drugs, a dose is considered as reduced if a 
non-zero dose is marked on the CRF as reduced. Dose adjustment due to BSA change is not counted as dose reduction as long as th e prescribed dose is  not lower than the 
protocol specified level. For Prednisone, due to the tapering regimen, dose after DAY 
5 in each cycle is not used in dose reduction consideration. 
 Dose withholding  to flag if the dose of the study medication is withheld at least once 
(one flag for each drug), excluding those due to schedule changes for VELCADE. A 
dose not given due to schedule change will not be counted as withholding for 
VELCADE. The number of withheld doses will be recorded for VELCADE and 
prednisone. 
 Schedule change  to flag if a schedule change of VELCADE is initiated within the 
cycle, i.e., if the VELCADE dose schedule is changed from twice weekly to once 
weekly. Note: this is applicable only for those subjects randomized to receive VcR-
CAP.  
 Dose modification  to flag if the dose of the st udy medication is modified (delayed, 
reduced or withheld, schedule change [for VE LCADE only]) at least once (one flag for 
each drug).   
 Number of doses  to record the number of nonzero actual doses given (one variable 
for each drug). 
 Total dose (mg)  to record the sum of nonzero doses (one variable for each drug). 
 Total doses (mg/m
2)  to record the sum of  nonzero doses per m2 (one variable for 
each drug), which equals the total dose (m g) divided by body surface area in that cycle. 
When the BSA is not available for the cycle of  interest, the most recent value is to be 
used. 
 
2.4.7. Dose Intensity and Relative Dose Intensity 
Dose intensity (mg/m2/cycle) will be calculated separate ly for the study drugs (VELCADE, 
rituximab, cyclophosphamide, doxorubicin, vincri stine, and prednisone) by cycle and 
overall. 
For each of the study drugs, the dose intens ity equals the sum of total dose (mg/m2) 
received in all cycles divided by th e number of cycles on that drug.  
The dose intensity per cycle is equal to the sum of the total dose (mg/m2) received in that 
cycle.  
JNJ-26866138 (VELCADE* [Bortezomib] for Injection) Statistical Analysis Plan LYM-3002 
 15The overall planned dose intensity is equal to the sum of the planned total dose (mg/m2) in 
all cycles divided by the numb er of cycles received.  
The planned dose intensity per cycle is equal to the sum of the planned total dose (mg/m2) 
in the cycle. When a subject receives all scheduled doses in a cy cle, the planned dose 
intensity per cycle for VELCADE is 1.3*4=5.2 (mg/m2/cycle); for rituximab, is 375*1=375 
(mg/m2/cycle); for doxorubicin, is 50*1=50(mg/m2/cycle); for cyclophosphamide, is 
750*1=750 (mg/m2/cycle); for vincristine, is 1.4*1=1.4 (mg/m2/cycle); for prednisone, is 
100*5=500 (mg/m2/cycle).  
The relative dose intensity is the ratio of the dose intensity and the planned dose intensity. 
2.4.8. Age and Age Categories 
Age will be calculated at the date of randomization. Integer values are used. The following 
categories of age will be adopted: 65 years, >65 years. 
2.4.9. Baseline Values 
The baseline value is defined as the value coll ected at the time closest to, but prior to, the 
date of first dose (inclusive). If a subject is not dosed, the date of randomization will be 
used.  
In case that laboratory values from both the cen tral lab and local lab are available before 
randomization, the values from central lab will be  used as baseline, even if the sample date 
of central lab result is prior to that of local lab value.  
2.4.10. Categories of Ex tranodal Sites of Disease 
Two categories will be used for the number of extranodal sites: 1 or >1.  
2.4.11. Category of Internat ional Prognosis Index (IPI) 
The IPI will be assessed according to the follo wing risk factors: age, stage of disease, 
performance status, number of extranodal sites,  and LDH level. A subjects’s IPI ranges 
from 0-5 and equals the number of the following applicable conditions: 
 Age >60 years 
 MCL stage III or IV at diagnosis 
 ECOG performance status score >1 at baseline 
 More than one extranodal site involvement at baseline 
 Baseline LDH > normal limits 
IPI at baseline will be classified into th e following categories: low (0-1 factor), 
low-intermediate (2 factors), high-interme diate (3 factors) an d high (4-5 factors). 
JNJ-26866138 (VELCADE* [Bortezomib] for Injection) Statistical Analysis Plan LYM-3002 
 16Categories of IPI are also used to determine the appropriate stratum in which a subject is 
to be randomized. Since evaluations at screening may be used to determine the 
stratification, a separate vari able is used to capture the value used in randomization. 
2.4.12. Stage of MCL at Diagnosis 
The staging of MCL at diagnosis is to be assessed using the American Joint Committee on 
Cancer NHL staging system. Those subjects with  Stages II, III, or IV disease are eligible 
for this study. 
Stage of MCL disease is also used to determ ine the appropriate stratum in which a subject 
is to be randomized. A separate variable is used to capture the value used in randomization. 
2.4.13. Creatinine Clear ance and Its Category 
Creatinine clearance is to be calculated using the following formulae.  
For male subjects,  
Creatinine clearance = ( 140 - Age [yrs]) * Weight [kg] / 72 / (Serum 
creatinine/88.4) 
For female subjects, 
Creatinine clearance = 0.85 * (140 – Age [yrs]) * Wei ght [kg] / 72 / (Serum 
creatinine /88.4). 
Integer values will be used. When available, creatinine cl earance values are divided into 3 
categories: 30 mL/min, 31-60 mL/min, and >60 mL/min. 
2.4.14. Time since Initial Diagnosis  
Time since initial diagnosis is defined for al l subjects and is calculated from the date of 
diagnosis to the date of randomization (month). 
2.4.15. Relationship of Adverse Events to Study Medication 
For each adverse event, its relationship to each  of the six study medicat ions is determined 
by the investigator and recorded on the CRF.  
An adverse event that occurs in the VcR- CAP arm is considered as related to study 
medication if it is possibly, probably or very li kely related to any one or combinations of 
the five study drugs (VELCADE, rituxi mab, cyclophosphamide, doxorubicin, and 
prednisone). The category of the relationship to study medication is to be the maximum of 
the relationship to the five individual study drugs (“Very Likely”>“Probable”> 
“Possible”> “Doubtful”> “Not Related”). 
JNJ-26866138 (VELCADE* [Bortezomib] for Injection) Statistical Analysis Plan LYM-3002 
 17An adverse event that occurs in the R-CHOP  arm is considered as related to study 
medication if it is possibly, probably or very li kely related to any one or combinations of 
the five study drugs (rituximab, cyclophos phamide, doxorubicin, vincristine, and 
prednisone). The category of the relationship to study medication is to be the maximum of 
the relationship to the five individual study drugs. 
An adverse event that occurs in the VcR-CAP-tr eated subjects is considered as related to 
VELCADE if it is possibly, probably or very likely related to VELCADE. 
2.4.16. Study Medication-Related Death 
A death is considered as rela ted to study medication if the ca use is recorded as adverse 
event, at least one of which is related to study medication.  
2.4.17. Dose Discontinua tion of A Specific Study Drug Due to Adverse 
Events 
The dose of a specific drug (VELCADE, rituximab, cyclophosphamide, doxorubicin, 
vincristine, and prednisone) may be discontinued due to adverse events while at least one 
of the other study drugs may be continuing. Su ch dose discontinuations will have Action 
Taken Regarding Trial Med being “permanently stopped” for the study drug of interest. The cycle in which the dose is discontinued is  to be the cycle in which the last nonzero 
dose of this study drug is given. 
2.4.18. Adverse Events Leading to Tr eatment Discontinuation, and Study 
Medication-Related Treat ment Discontinuation 
The CRF collects adverse events that lead to discontinuation of any of the six study drugs. 
For an adverse event to be considered as the reason for treatment discontinuation, the 
following two conditions must be met: 
1) The action taken regarding trial medicati on due to this adverse event should be 
“permanently stopped” for at leas t one of the study drugs; and  
2) This subject should be indicated by the investigator to have discontinued study 
treatment due to adverse events. 
A subject is considered as discontinued due to study medication-relate d adverse events if 
(1) the reason for treatment discontinuation is adverse event, and (2) at least one of the 
adverse events leading to treatment disconti nuation, as defined above, should be related to 
study medication. 2.4.19. Linking of  Adverse Events 
To analyze new onsets of adverse events, ove rlapping/adjacent adve rse event records of 
the same preferred term may need to be linked. This is due to the AE collection procedure 
JNJ-26866138 (VELCADE* [Bortezomib] for Injection) Statistical Analysis Plan LYM-3002 
 18as follows. For an adverse event recorded on the CRF, whenever a feature of the adverse 
event changes (e.g., changes in grade/seriousness/action taken) , a new adverse event record 
will be entered to reflect the change. For exampl e, if the toxicity of an AE changes, the 
altered toxicity must be reco rded on a new line. Resolved date and Onset date must not 
overlap from 1 line to another for more than 1 day. For the first degree of toxicity, the 
Resolved date must be filled. A new line shou ld list the same AE, a new Onset date, and 
the new degree of toxicity. All the adverse event records of the same preferred term from 
the same subject are to be linked by the onset  date and the resolution date. If a resolved 
event is followed by another event of the same preferred term with the onset date within 1 
day of the resolution date of the previous r ecord, these 2 records s hould be linked together 
and considered as 1 event. 
2.4.20. Concomitant Medication During Treatment 
Concomitant medications administered duri ng study treatment includ e those concomitant 
medication records that are indi cated in the CRF as not bei ng prior therapy, and have the 
onset date, possibly imputed, no earlier than treatment start a nd no later than the treatment 
end. 
2.4.21. Categories of  Body Surface Area 
Three categories of body surface area are of interest: <1.5 m2, 1.5-2 m2, and >2 m2. 
2.4.22. Censoring Reasons for PFS 
Those subjects who are censored for PFS will be classified into the following categories: 
subsequent therapy, lost to follow-up, missed tumor assessments before death, and study 
cut-off.  
The Censoring reasons for PFS are defined as below: 
1) Subsequent therapy: if subsequent therapy is  started before PFS events (i.e., PD or 
death).  
2) Lost to follow-up: if the reason for end of  data collection is lost to follow-up, 
subject choice, or other. 
3) Missed tumor assessments before death: if a subject died more than 6-month after 
last adequate tumor assessment. 
4) Date of clinical cut-off/study closed by sponsor: for subjects without PD at the 
time of clinical cut-off/ study closed by sponsor for analysis. 
Refer to the Table 1 in Section 5.2.1 for more details of censoring method. 
JNJ-26866138 (VELCADE* [Bortezomib] for Injection) Statistical Analysis Plan LYM-3002 
 192.4.23. Censoring Reasons for Overall Survival 
Those subjects who are censored for OS will be classified into the following categories:  
1) Lost to follow-up: the reason for end of da ta collection is lost to follow-up, subject 
choice, or other. 
2) Study cut-off: subjects who are still alive as of the date of clinical cut-off. 
 
3. INTERIM ANALYSIS AND DATA MO NITORING COMMITTEE REVIEW 
An Independent Data Monitoring Committee (IDMC) has been commissioned for this 
study. There will be three interim an alyses planned in the study.  
The first interim analysis will occur after the first 100 subjects have been randomized into 
the study and will assess the safety and conc ordance rate of the diagnosis of MCL when 
central review is compared to the inve stigator assessment of the diagnosis.  
The concordance rate of the diagnosis of MCL will also be reviewed at 50% accrual in a 
blinded manner. If the observed concordance rate is 95% (95% CI: [91%, 97%]), the 
sample size for the study will not be changed. If the observed difference is less than 95%, 
the sample size may be adjusted to provide adequate events (approximately 280) in those 
subjects with a centrally c onfirmed MCL diagnosis for the final analysis (295 PFS events 
in total). There is no alpha adjustment for the 1st interim analysis since no efficacy analyses 
will be performed.  
The first interim analysis will also review the sa fety data collected to date. Safety data will 
be reviewed after at least one cycle for the fi rst 100 treated subjects, irrespective of whether 
they complete treatment within that first cycle. The second interim analysis will review the safety data and will be performed after 
100 subjects per arm have either completed or  discontinued study trea tment, which allows 
sufficient exposure for review  of cumulative toxicity. 
JNJ-26866138 (VELCADE* [Bortezomib] for Injection) Statistical Analysis Plan LYM-3002 
 20The third interim analysis has been planned fo r this study after at least 148 events have 
occurred. If, at the interim analysis, pre-spec ified boundaries for PFS are met then the study 
may be terminated and superiority of the experimental arm (VcR-CAP) will be declared 
over the comparator arm (R-C HOP). If the observed hazard ratio (R-CHOP vs. VcR-CAP) 
for PFS in the third interim analysis is equa l to or less than 1.03 (a value of >1 favoring 
VcR-CAP), then the study may be terminated  due to futility. The conditional power would 
be <30% with the observed hazard ratio (HR) 1.03 at the third interim analysis and the 
future HR of 1.4, which suggests low probabili ty of success at the end of the study. There 
will also be a review of the safety data at the third interim analysis. 
The stopping boundary for the interim is to be calculated using the observed number of 
PFS events at the data cutoff using the O’ Brien-Fleming spending function. The alpha 
allocated for the interim is 0.003 (2-sided) with 148 events, and is 0.049 (2-sided) for the 
final analysis.  
If pre-specified boundaries are no t met at the interim stage, th e final analysis of the study 
will occur after 295 events. 4. SUBJECT INFORMATION 
4.1. Demographics and Baseline Characteristics 
All demographic and baseline characteristic va riables will be summa rized for both the ITT 
and the PP populations. 
Subject enrollment will be summarized by regi on, country, and investigator. Also to be 
summarized is subject eligibility by m eeting inclusion/ex clusion criteria. 
Stratification factors used in randomization (IPI  category and stage of disease at baseline) 
will be tabulated. The stratified logrank test an d stratified cox model use the stratification 
factors in randomization.  
Demographic and baseline characteristic data will be summarized, including sex, age, race, 
ECOG performance status score, we ight, height, and body surface area (m
2).   
The following categories of disease characte ristics at baseline will be summarized: 
1) Diagnosis information of MCL: includi ng confirmed diagnosis by central review 
(Yes, No, or indeterminate), stage of di sease at diagnosis, type of histology, 
cellularity, over-expression of cyclin D1 in association with CD20 and CD5 (Yes 
or No), and chromosome transloc ation t(11; 14)  (Yes or No). 
JNJ-26866138 (VELCADE* [Bortezomib] for Injection) Statistical Analysis Plan LYM-3002 
 212) Disease characteristics at baseline: includi ng IPI at baseline, bone marrow aspirate 
results (Positive, Negative, Indeterminate, or Not Evaluable), bone marrow biopsy 
results (Positive, Negative, Indeterminat e, or Not Evaluable), baseline LDH 
(absolute value and category [>ULN, ULN], and reason for transplantation 
ineligibility. 
Baseline IPI score and baseline stage of disease will be deri ved or obtained from CRF. 
These baseline derived stratific ation factors will be tabulated and they will be used in the 
subgroup analyses.  
Two panels of baseline clini cal laboratory tests will be su mmarized: hematology and serum 
chemistry. Descriptive summaries for creatin ine clearance and categories of creatinine 
clearance will be provided. Frequencies of CTC grade are to be provided for the following 
laboratory tests at baseline:  Hematology: hemoglobin, WBC, absolute neut rophil count (ANC), ab solute lymphocyte 
count (ALC), and platelets. Chemistry: aspartate transaminase (AST),  alanine transaminase (ALT), bilirubin, 
creatinine, alkaline phosphatase, glucose, albumin, bicarbonate, magnesium, LDH, urea, 
blood urea nitrogen, uric acid, electrolytes (sodium, potassium, calcium, and phosphate), 
and creatinine clearance. 
Medical history will be summarized. The findings (normal or abnormal [clinically 
significant or clinically insignificant]) will also be summarized for baseline 12-lead ECGs, 
and ECHO/MUGA scans. 
4.2. Disposition Information 
A CONSORT-type flow chart of subject disposition will be provided for the intent-to-treat 
population.  
The number of subjects discontinuing and completing the study treatment will be reported 
for the intent-to-treat populat ion. The reasons for disconti nuation as indicated by the 
investigators will be summarized by the numbe r of subjects reporting. Those subjects who 
discontinue study treatment due to adverse even ts will be further tabulated by relationship 
to study medication. The number and percentage of subjects in the safety population and the per-protocol populations will also be reported. 
Descriptive statistics (mean, standard devia tion, median, and range) will be provided for 
study duration (in weeks) as well  as length of follow-up (in m onths) for the intent-to-treat 
and the per-protocol populations. 
JNJ-26866138 (VELCADE* [Bortezomib] for Injection) Statistical Analysis Plan LYM-3002 
 224.3. Extent of Exposure 
All extent-of-exposure summaries are to be presented for the safety population. 
Frequency of subjects who receiv e at least a certain number of  treatment cycles will be 
tabulated by the number of cycles. Number of  treatment cycles will be summarized along 
with time on study treatment, and dose intensity for the study drugs. 
Summaries will be provided for number of doses and total doses of study drug (mg/m2) by 
cycle. Also to be presented by cycle are the number and percenta ge of subjects on 
treatment, and the number and percentage of s ubjects with cycle delays (>5 days). For each 
of the study drugs, the followi ng summaries are to be report ed: number of subjects dosed, 
number of subjects with dose reduced, dose wit hheld, schedule change (only applicable to 
subjects treated with VELCADE), and any ch ange in dosing (reduced, withheld, schedule 
change [VELCADE only]).  Reasons for dose modifications will be summ arized by cycle as well as across the study 
for each of the following changes: cycle delay, dose reduction, dose withholding, and 
schedule change (VELCADE only).  For each type of the dose changes mentione d above, adverse events leading to these 
changes in doses of study treatment will be summarized for each of the study drugs.  
Adverse events leading to the discontinua tion of VELCADE will be summarized in a 
separate summary. In this summary, the incidenc es of the following AE s are to be reported: 
AEs leading to the discontinuation of VELCADE  alone, AEs leading to the discontinuation 
of VELCADE and at least one other study drug, and AEs leading to the discontinuation of 
study treatment. 
4.4. Protocol Deviations   
Major protocol deviations will be summarized by types of deviations.  
4.5. Concomitant Medications  
Concomitant medications will be coded using the latest version of the WHO Drug 
Dictionary. The concomitant therapies will  be provided by therapeutic class, 
pharmacological class, and preferred term. A summary of all concomitant medications will 
be summarized, including the ones that (1) st arted prior to study treatment and continued 
during study treatment (2) started during st udy treatment. A separate summary will be 
provided for concomitant therapie s started during study treatment.  
 
JNJ-26866138 (VELCADE* [Bortezomib] for Injection) Statistical Analysis Plan LYM-3002 
 234.6. Subsequent Therapies for MCL 
Subsequent therapies for MCL, including antineoplastic agents and other systemic 
therapies such as steroids, will be summarized by pharmacological class and preferred 
term. In addition, the number and percenta ge of subjects who receive VELCADE as 
subsequent therapy will be presented. These summaries are to be provided for both the ITT 
and the PP populations. 
Best responses to subsequent anti-lymphoma therapies will be tabulated. 
5. EFFICACY 
5.1. Analysis Specifications 5.1.1. Level of Significance 
All tests will be 2-sided. The primary popul ation is the ITT populat ion, with sensitivity 
analyses to be performed on the centrally confirmed MCL population and PP populations. 
The primary hypothesis is to be tested at  the 0.05 significance level (overall). The 
significance level at an interim analysis is  to be determined by the observed number of 
events at the time of the interim analysis per the O’Brien-Fleming spending function. 
The secondary hypotheses are to be tested sequentially at the nominal 0.05 significance 
level. The order of these hypotheses is as follo ws: 1) TTP, 2) TNT, 3) CR rate and 4) OS. 
A secondary hypothesis will be tested if and onl y if the primary hypothesis is rejected along 
with all the secondary hypot heses that precede it.  
OS will be analyzed regardless of what happe ned to the other endpoints in the hierarchical 
test.  
For exploratory modeling, main effects other than the treatment group in a proposed model 
will be tested at the 0.05 significance level, wh ile interactions will be  examined at the 0.10 
significance level. Non-significant interacti on terms will be removed from the model. 
The clinical cutoff of the third interim analys is was 5 July 2011. At the time of clinical cut-
off, there were 173 PFS events. Based on the or iginal design with an O’Brien-Fleming 
spending function (the Lan-DeMets  approach) and a total of 295 events, an alpha allocated 
for the 3
rd interim analysis is 0.006 (2-sided), and fo r the final analysis is 0.048 (2-sided).  
5.1.2. Data Handling Rules 
Unless specified otherwise, missing values for efficacy criteria will be handled using the 
last-observation-carried forward method. Baseline  values of efficacy cr iteria will not be 
carried forward. 
JNJ-26866138 (VELCADE* [Bortezomib] for Injection) Statistical Analysis Plan LYM-3002 
 245.1.3. Definitions for So me Efficacy Variables  
5.1.3.1. Tumor Assessment by I ndependent Radiology Review 
Committee (IRC) 
Tumor assessment by radiological images (c omputed tomography [CT] scans) is the 
primary efficacy evaluation.  All radiological  images will be collected and reviewed 
centrally by Perceptive Informatics, an I ndependent Radiology Review committee (IRC).  
The radiological images will be collected at baseline, Cycles 2, 4, 6 (and 8, if applicable), 
End-of-Treatment, and thereafter every 6 weeks for 18 weeks and every 8 weeks until 
PD/initiation of alternate therapy/withdraw al. With the approval of Amendment INT-3, 
when the subject is recorded to  have an event of PD, a repeat  CT scan to confirm PD must 
be undertaken at least 30 days after the scan th at was used to determine PD. In the event a 
subject starts subsequent anti-lymphoma treat ment, it is strongly recommended that this 
repeat CT scan be performed before the subject starts treatment. The repeat CT scan must 
be done using i.v. and oral contra st and must be of the neck, chest, abdomen, and pelvis. If 
the subject is intolerant of i .v. contrast agents, the scan may be performed with only oral 
contrast. 
The IRC will consist of a minimum of 3 board certified radiologists assigned to 
Study LYM-3002. Two primary radiologists will independently read each case (double 
read) with a third radiologist serv ing as adjudicator, when necessary. 
The primary radiologists will independently inte rpret imaging studies for subjects enrolled 
in the study, using modified International Workshop to Standardize Response Criteria for 
non-Hodgkin’s Lymphoma (IWRC) [Cheson 2007]).  Detailed criteria for response 
categories can be found in the attachment to this SAP. The ra diologists will be blinded to 
treatment assignment.  
The IRC primary radiologists will assess st udy imaging to determine overall tumor 
response at each timepoint (CR, CRu, PR, SD, or  PD). The adjudicator will evaluate cases 
where disagreement exists between the primary radiologists and will choose one of the 
primary reviewer’s assessments as the final assessment. The IRC primary radiologists will 
review all timepoints available for e ach subject in a sequential fashion.  
5.1.3.2. Date of Progression 
For analyses based on the IRC tumor assessment, the date of progression  will be the earliest 
date of PD from imaging studies. 
For analyses based on the inves tigator’s tumor assessment, the date of progression will be 
the earliest date of PD from  imaging study (collected on Ev aluation of Response page on 
JNJ-26866138 (VELCADE* [Bortezomib] for Injection) Statistical Analysis Plan LYM-3002 
 25CRF) or date of PD other than imaging study (c ollected on PD page of  CRF), whichever is 
first reported.   
5.1.3.3. Complete Response Assessment 
Overall complete response refers to CR and CRu, defined by meeti ng the requirements for 
CR/CRu per the modified IW RC criteria (Attachment) . 
A CR must meet the CR criteria based on radiological imaging study, and subsequently 
verified by the laboratory te sts with normal LDH and negati ve bone marrow at screening 
or at the time of the radiological CR (from central pa thology laboratory 
Phenopath/Covance). A CRu is CRu base d on radiological imaging study, and 
subsequently verified by laboratory tests with normal LDH and negative bone marrow at 
screening or normal LDH and negative/inde terminate bone marrow at the time of the 
radiological CRu.  
Radiological overall complete response refers  to radiological CR/CRu  verified or not 
verified by LDH and bone marrow. Radiol ogical CR/CRu is defi ned by CR/CRu meeting 
all the criteria for CR/CRu based on radiol ogical imaging studies, but subsequent 
verification by LDH and bone marrow findings is  not required. The date of radiological 
CR/CRu is the first date that CR/CRu is doc umented (tumor assessment per IRC) based on 
radiological imaging study. 5.1.3.4. Tumor Assessment by Investigator 
Tumor assessment will be performed by investigators locally based on radiological images 
and using the same modified IWRC criteria.  Overall tumor assessment by the investigators 
at each timepoint is collected in the CRF.  In  addition, tumor assessment of PD can also be 
done based on clinical evidence other than radiological images, which is collected in the CRF.  Analyses for investigator tumor assessment are secondary analyses. 
5.1.3.5. Best Overall Response 
The best overall response is the best response recorded from the start of the treatment until 
disease progression or the start of s ubsequent anti-neoplastic therapy.  
5.2. Primary Efficacy Endpoint(s) 
5.2.1. Definition  
The primary endpoint is PFS,  which is defined as the interval between the date of 
randomization and the date of PD  or death, whichever is first reported, in the ITT population. 
Subjects who withdraw from the study (i.e., withdr awal of consent, lost to follow-up) or start 
anti-neoplastic therapy without documented PD will be censored  at the time of the last 
adequate (CT scan available) disease assessment. Subjects who complete the study, have not 
JNJ-26866138 (VELCADE* [Bortezomib] for Injection) Statistical Analysis Plan LYM-3002 
 26progressed, and are still alive at the cut-off date of the final analysis w ill be censored at the 
last adequate disease assessment. For PD documented between scheduled evaluations, the 
actual date of PD will be used , not the date of the next sc heduled evaluation. For death no 
more than 6-month after last disease assessment, the date of the even t will be the date of 
death. For death more than 6- month after last disease assess ment, the PFS will be censored 
at the last adequate disease assessment. The censoring method is summarized in Table 1.  
Table 1:  Censoring Method 
Situation  Date of Progression or Censoring Outcome  
No baseline tumor assessments  Randomization Censored  
Progression documented between 
scheduled visits  Earliest date of radiological assessment documenting progression PFS event   
No progression  Date of last visit with adequate assessment Censored  
New anticancer treatment started Date of last visit with adequate assessment (prior to subsequent anticancer treatment)Censored  
Death before first PD assessment  Date of death PFS event  
Death between adequate assessment visits  Date of death  PFS event  
Death within 6-month after last 
disease assessment Date of death PFS event 
Death more than 6-month after last 
disease assessment Date of last visit with adequate assessment Censored 
 
The primary analysis for PFS will be based on IRC assessment of PD. Progression-free 
survival derived from investigator data will be evaluated and used as supportive evidence. 
Sensitivity analysis on PFS using IRC alternative assessments of transient fluid collection 
or transient lesion as basis for PD will be performed. 
The primary analysis for PFS will also be conducted among the subjects with centrally 
confirmed MCL. Sensitivity analysis for PFS will be conducted by not censoring a subject who started 
subsequent antineoplastic therapy without documented PD. Sensitivity analysis for PFS 
will also be conducted by censoring a subject whose PD is after more than one missing 
adequate disease assessment and censoring date is the last adequate disease assessment 
before PD. 
5.2.2. Analysis Methods 
The Kaplan-Meier method will be used to estimate the distribution of overall PFS for each 
treatment group. The primary treatment comparis on is based on a strati fied log-rank test. 
Hazard ratio and its 95% confidence interval ar e to be estimated based on a stratified Cox’s 
JNJ-26866138 (VELCADE* [Bortezomib] for Injection) Statistical Analysis Plan LYM-3002 
 27model with treatment as the explanatory variable. Stratification factors include 
International Prognostic Index (IPI:  0-1, 2, 3, and 4-5) and stage of  disease at diagnosis (II, 
III, and IV). The sensitivity analyses fo r PFS among centrally confirmed MCL subjects, 
for PFS without censoring subsequent therapy, and for PFS censoring after more than one 
missing adequate disease assessment will be performed similarly. 
The unstratified log-rank test will also be performed as a sensitivity analysis.  
The subgroup analyses for PFS will be done as specified in Section 2.3. 
A Cox’s regression model will be used in sensitivity analyses. It is intended to estimate the 
effect size of VcR-CAP vs. R-CHOP after acc ounting for prognostic factors. The following 
prognostic factors will be included  in the analysis: age (>65, 65), sex, race (white, non-
white), baseline ECOG performance status ( 1, >1), baseline extranod al site involvement 
(1, >1), baseline LDH (normal, above normal limits), and WBC (normal, above normal 
limits),  together with stage of dis ease at diagnosis (II and III vs. IV).  
Concordance rate between investigator PD a nd IRC PD will be provided.  Agreement on 
PD status includes PD by both IRC and investigator or no PD by both of them. In addition, 
PD by both IRC and investigator will be categorized into sub categories of complete agreement, agreement with later date, or agr eement with early date.  Disagreement on PD 
status includes PD by investigator but not  IRC and PD by IRC but not investigator. 
The total number of PD even ts adjudicated will be given.  For subjects without PD, the 
main reason for censoring will also be tabulated.  
5.3. Major Secondary Endpoints 
5.3.1. Definition 
Time to Progression 
Time to Progression is defined as the duration from the date of randomization until the date 
of first documented evidence of PD or rela pse for subjects who experience CR or CRu on 
this study. Death due to PD will be  considered as an event if the date of death is within 6-
month after last disease assessm ent, otherwise, death will be censored at the date of last 
disease assessment. Subjects w ho withdraw from the study (i.e., withdrawal of consent, 
lost to follow-up) or start subsequent therapy or die of causes other than PD will be 
censored at the time of the last disease assessment. 
JNJ-26866138 (VELCADE* [Bortezomib] for Injection) Statistical Analysis Plan LYM-3002 
 28Overall Response Rate (ORR) 
Overall Response Rate is defined as the pr oportion of subjects who achieve CR, CRu, or 
PR relative to the response evaluable populat ion. Disease response and progression will be 
evaluated according to the modified IWRC.   
Complete Response (CR/CRu) Rate 
Complete response rate is defined as the proportion of subjects who achieve CR or CRu 
relative to the response evaluable population.   
Radiological complete response rate is define d as the proportion of subjects who achieve 
radiological CR or radiological  CRu relative to the res ponse evaluable population.   
Time to Next Antilymphoma Treatment  
Time (days) to next anti-lymphoma treatment is measured from the date of randomization 
to the start date of new anti-lymphoma treatment.  Death due to disease progression prior 
to subsequent therapy is cons idered as an event.  Otherw ise, time to next anti-lymphoma 
treatment is censored at the date of death or the last date known to be alive.  
Overall Survival (OS) 
Overall survival is measured from the date of randomization to the date of the subject’s 
death. If the subject is alive or  the vital status is unknown, OS will be censored at the date 
that the subject is last known to be alive. 
Duration of Response and Duration of Complete Response 
Duration of radiological response (CR, CRu, or PR) will be calculate d from the date of 
initial documentation of a response to the date of first documented evidence of PD or death 
due to PD.  Responders who wit hdraw from the study (i.e., withdr awal of consent, lost to 
follow-up) or who start subsequent anti-neoplas tic therapy without documented PD will be 
censored at the time of the la st adequate (CT scan ava ilable) disease assessment. 
Responders who complete the study, have not pr ogressed, and who are still alive at the cut-
off date of the final analysis will be censored at the last adequate disease assessment. For 
death due to PD  more than 6-month after last disease assessment, the duration will be 
censored at the last adequate disease assessment before PD or death.    
Duration of complete response (CR, CRu) wi ll be calculated from the date of initial 
documentation of a complete response to the da te of first documented evidence of PD or 
death due to PD.  Subjects w ho have a complete response wi thout disease progression or 
death due to PD will be censored in the same way as in duration of response.  
JNJ-26866138 (VELCADE* [Bortezomib] for Injection) Statistical Analysis Plan LYM-3002 
 295.3.2. Analysis Methods 
Time to Progression 
The analysis method will be similar to that used for the primary PFS. The analysis of TTP 
is considered sensitivity analyses for PFS. 
Response-Related Endpoints 
The number and percentage of subjects in  the following response categories will be 
presented by treatment group: complete res ponse (CR), unconfirmed complete response 
(CRu), overall complete response (CR+CRu),  partial response (PR), overall response 
(CR+CRu+PR), stable disease (SD) , and progressive disease (PD). 
Overall Response Rate (ORR) 
Overall response rate is to be pr esented by treatment group. Stratified 
Cochran-Mantel-Haenszel (CMH) test will be used to test treatment difference.  The 
Mantel-Haenszel estimate of odds  ratio and its 95% confidence interval are to be presented 
as well. 
Both ORR based on IRC assessment (primary ) and on investigator assessment (supportive) 
will be evaluated and analyzed for the response evaluable population.  
Complete Response (CR/CRu) Rate 
Both complete response rate and radiological complete response rate are to be presented 
by treatment group. Stratified CMH test will be used to test treatment difference. The 
Mantel-Haenszel estimate of odds  ratio and its 95% confidence interval are to be presented 
as well. 
Analyses will be based on the response evaluable population. 
Time to Next Antilymphoma Treatment  
The Kaplan-Meier method will be used to es timate the distribution of time to next 
anti-lymphoma treatment for each treatment group. The primary treatment comparison is 
based on a stratified log-rank test. The hazard ratio and its 95% confidence interval are to 
be estimated based on the Cox’s regression model.  
Overall Survival (OS) 
The Kaplan-Meier method will be used to estimat e the distribution of OS for each treatment 
group. The primary treatment comparison is base d on a stratified log-ra nk test. Hazard ratio 
and its 95% confidence interval are to be es timated based on a stratif ied Cox’s model with 
treatment as the explanatory variable. Stratifi cation factors in clude International Prognostic 
Index (IPI: 0-1, 2, 3, and 4-5) and stage of disease at diagnosis (II, III, and IV).  
JNJ-26866138 (VELCADE* [Bortezomib] for Injection) Statistical Analysis Plan LYM-3002 
 30In addition, the probability of su rvival at 18 months and 3- year after randomization, based 
on Kaplan-Meier estimates, will  be presented for the 2 treatment groups, along with their 
95% confidence interval. 
Duration of Response and Duration of Complete Response 
The Kaplan-Meier method will be used to de scriptively summarize duration of response 
and duration of complete response. 
5.4. Other Efficacy Variables 
5.4.1. Definition 
Time to Response   
Time (days) to response is measured from th e date of randomization to  the date of initial 
response (CR, CRu, or PR). Those subjects without response ( CR/CRu/PR) will be 
censored either at PD or at the last efficacy  assessment before the start of subsequent 
therapy. 
Rate of Durable Response  
A durable response is defined as a re sponse (CR, CRu, PR) with a duration 6 months.  
The rate of durable response is the proportion of subjects who achieve durable response 
relative to the response evaluable population.   
Duration of Treatment Free Interval  
Duration (days) of treatment free interval is m easured from the date of last dose plus 1 to 
the start date of the new treatment.  
Death due to disease progression prior to subse quent therapy is considered as an event.  
Otherwise, treatment-free interval is censored at  the date of death or the last date known to 
be alive. 
5.4.2. Analysis Methods 
Time to Response   
The Kaplan-Meier method will be used to es timate the cumulative distribution over time 
for time to response in the response evaluable population. The stratified  log-rank test will 
be used to compare the 2 treatment groups.  In addition, descriptive summaries are to be 
provided for time to response for responding subjects (CR/CRu/PR). 
Rate of Durable Response  
For rate of durable response, the analysis me thod will be similar to the one used for ORR. 
For subjects who don’t have durab le response, number s of subjects whose best response is 
worse than PR,  numbers of subjects whose be st response are better  or equal PR with 
JNJ-26866138 (VELCADE* [Bortezomib] for Injection) Statistical Analysis Plan LYM-3002 
 31censored value and duration <6 months,  and num bers of subjects w hose best response are 
better or equal PR with event and durati on <6 months will be given separately. 
Duration of Treatment Free Interval  
The Kaplan-Meier method will be used to descriptively summarize the duration of the 
treatment-free interval.    
Subsequent Anti-Lymphoma Therapy 
Frequency tabulation will be given, indica ting how many subjects in each group started 
subsequent therapy.  
6. SAFETY 
Safety of the treatment arms will be compared using the incidence and severity of adverse 
events, laboratory test results, ECG/echo or MUGA results, vital sign measurements, 
physical examination results, mortality, and ECOG performance status.  
Safety analyses will be performed by the treatm ent actually received. Th at is, those subjects 
who are randomized to VcR-CAP but never r eceive VELCADE will be analyzed in the R-
CHOP group (Treatment Arm B), and t hose who are randomized to R-CHOP but 
mistakenly receive at least one dose of VELCADE will be analyzed in the VcR-CAP group 
(Treatment Arm A). 
MRU data will be analyzed in a separate report. 
6.1. Adverse Events 
Treatment-emergent adverse events are defined as any adverse event that occurs on or after 
administration of the first dose of st udy medication (VELC ADE, rituximab,  
cyclophosphamide, doxorubicin, vincristine, and prednisone) and through the End of 
Treatment visit to 30 days afte r the last dose of study drug, a ny event that is considered 
drug-related (very likely, probabl y or possibly related) regardle ss of the start date of the 
event, or any event that is present at baseline but worsens in intensity or is subsequently considered drug-related by the investigator.   
The most recent MedDRA dictionary will be us ed to code the investigator’s adverse event 
terms. Adverse event tables will summarize subject incidence by treatment group actually 
received. The severity of adverse ev ents will be assessed using NCI CTC v3.0. 
6.1.1. All Adverse Events 
The incidence of treatment-emergent adverse events will be summarized.  The following 
tabulations will also be presented: 
JNJ-26866138 (VELCADE* [Bortezomib] for Injection) Statistical Analysis Plan LYM-3002 
 32 Overview of treatment-emergent adverse events 
 Incidence of treatment-emergent adverse events, especially the most commonly 
reported events (i.e., those events reported by at least 10% of subjects) by MedDRA 
SOC and preferred term. 
 Incidence of treatment-emergent adverse even ts by SOC, high level term, and preferred 
term. 
 Incidence of treatment-emergent adverse even ts considered by the investigator to be 
related to study medication, by SOC and preferred term. 
 Incidence of treatment-emergent adverse events by relationship to study medication. 
 Incidence of treatment-emergent adve rse events by CTC toxicity grade.  
 Incidence of treatment-emergent adverse even ts by CTC toxicity grade and relationship 
to study medication. 
 Incidence of AEs leading to  withdrawal from treatment by SOC and preferred term 
 Incidence of AEs leading to dose reduction, dose withholding, and cycle delay by SOC 
and preferred term 
 Incidence of treatment-emergent adverse even ts leading to death by system organ class 
and preferred term. 
 Incidence of AEs leading to the disconti nuation of VELCADE alone, AEs leading to 
the discontinuation of VELCADE and at least one othe r study drug, and AEs leading 
to the discontinuation of study treatment.  
 
Incidence of treatment-emergent adverse events (overview, all events, Grade 3, and 
serious) will also be summarized by Cycles 1, 2-3, 4-6, vs. >6. In case a subject experiences 
multiple adverse events of the same preferre d term during the study, a ll new onsets will be 
summarized. For treatment-emergent adverse events with CTC toxici ty grade of 3 or 
higher, the following summari es are to be produced. 
 Incidence of Grade 3 treatment-emergent adverse events, by SOC and preferred term.   
 Incidence of Grade 3 treatment-emergent adverse events considered by the 
investigator to be related to study medication, by SOC and preferred term. 
 Incidence of Grade 3 treatment-emergent adverse ev ents by relationship to study 
medication. 
For treatment-emergent serious adverse ev ents, the following summaries are to be 
produced. 
 Incidence of treatment-emergent serious a dverse events, by SOC and preferred term.   
 Incidence of treatment-emergent serious adverse events considered by the investigator 
to be related to study medicat ion, by SOC and preferred term. 
JNJ-26866138 (VELCADE* [Bortezomib] for Injection) Statistical Analysis Plan LYM-3002 
 33 Incidence of treatment-emergent serious a dverse events by relationship to study 
medication. 
Analyses of adverse events leading to treatment discontinuation are specified in 
Section 2.4.18. 
6.1.2. Adverse Events of  Clinical Interest 
Unless specified otherwise, the adverse events in this section are treatment-emergent ones. 
6.1.2.1. Peripheral Neuropathies 
Definition 
Peripheral neuropathies (PN) refer to the advers e events in the high level term of peripheral 
neuropathies NEC. 
All the PN event records of the same preferred term from the same subject are to be linked 
by the onset date and th e resolution date. If a resolved event is followed by another event 
of the same preferred term with  the onset date within 1 day of the resolution date of the 
previous record, these 2 records should be linked together and considered as 1 event. 
A PN event is considered as resolved if its final outcome is resolved with no subsequent 
PN event of the same preferred term occurring on the resolution date or the day before and 
after. 
A PN event is considered as improved if the event improves from the maximum grade. 
That is, all the grades record ed after the maximum grade is less than the maximum grade. 
Time to first onset of peripheral neuropathy events (any grade, grade 2, and grade 3) is 
measured from the first dosing date to  the initial onset date of event. 
Time to improvement and time to resolution are to be defined for each PN event. 
Time to resolution is defined as the number of  days from the initial onset date (inclusive) 
to the resolution date for resolved events. Those events that are not resolved will be 
censored at the date of last study drug dose pl us 30 days for Grade 1 events (or the data 
cut-off if earlier) and the date of last study dr ug dose plus 180 days for Grade >=2 events 
(or the data cut-off if earlier). This is in line with the protocol specifications on adverse 
event reporting, indicating that unresolved ne uropathic adverse events Grade 2 or higher 
should be followed for a maximum of 6 months, while general adverse events are reported 
until at least 30 days following  last dose of study medication 
(Protocol 26866138LYM3002, Section 9.6) 
JNJ-26866138 (VELCADE* [Bortezomib] for Injection) Statistical Analysis Plan LYM-3002 
 34For improved events, time to improvement is defi ned as the number of days from the initial 
onset date (inclusive) of the maximum grade to the first onset date that the toxicity grade 
is below the maximum grade with no higher grade thereafter, or the resolution date, 
whichever occurs first. For those events that stay at the maximum grade until the end of 
follow-up, time to improvement will be censored at the date of last study drug dose plus 
180 days if the maximum grade is at least 2, and the date of last  study drug dose plus 
30 days for Grade 1 events. 
Method 
The incidence of treatment-emergent periphe ral neuropathies will be summarized by high 
level term and preferred term.  Kaplan-Meier estimates of probability of de veloping peripheral neuropathy events (any 
grade, grade 2, and grade 3) will be presented for time to the first onset in the two 
treatment arms, and for cumulative VELCADE dose up to the first onset in the VcR-CAP 
arm. Subjects without any peripheral neuropathy events will be  censored at 30 days after 
last dose, or at total VELCADE dos e received in these analyses.  
Furthermore, time to improvement and time to resolution of peripheral neuropathy events 
will be summarized by outcome (improvement  or resolution) using the Kaplan-Meier 
method. This analysis is event based, thus 1 subject could contribute multiple observations if the subject has more than 1 PN event. 
6.1.2.2. Cardiac Rhythm and Conduction Abnormalities 
Definition 
Cardiac rhythm and conduction abnormalities in clude adverse events in the following high 
level terms (HLTs): cardiac conduction diso rders, cardiac signs and symptoms NEC 
(palpitations only), rate and rhythm disord ers NEC, supraventricular arrhythmias, 
ventricular arrhythmia s, and cardiac arrest. 
Method 
The incidence of treatment-emergent adverse events associated with cardiac rhythm and 
conduction abnormalities will be tabulated.  
6.1.2.3. Heart Failure 
Definition 
This endpoint refers to those adverse events coded to the following preferred terms: acute 
left ventricular failure, acute pulmonary oe dema, acute right ventricular failure, cardiac 
asthma, cardiac failure, cardiac failure acute , cardiac failure chronic, cardiac failure 
congestive, cardiac failure high output, car diogenic shock, cardiopulmonary failure, 
JNJ-26866138 (VELCADE* [Bortezomib] for Injection) Statistical Analysis Plan LYM-3002 
 35cardiorenal syndrome, chronic le ft ventricular failure, chronic right ventricular failure, cor 
pulmonale,  cor pulmonale acute, cor pulmona le chronic, ejection fraction decreased, 
hepatic congestion, hepatojugu lar reflux, left ventricular failure, low cardiac output 
syndrome, neonatal cardiac failure, pulmona ry oedema, pulmonary oedema neonatal, 
ejection fraction decreased, and diastolic dysfunction. 
Method 
Incidence of treatment-emergent heart failure events will be summarized. 
6.1.2.4. Pericardial Disease 
Definition 
Pericardial disease includes adverse events in the high level group term (HLGT) of 
“Pericardial disorders” a nd high level term of noninfectious pericarditis.  
Method 
The incidence will be presented. 
6.1.2.5. Acute Diffuse Infi ltrative Pulmonary Disease 
Definition 
This endpoint refers to those a dverse events coded to the foll owing preferred terms:  acute 
interstitial pneumonitis, acute respiratory distress syndrome, allergic granulomatous 
angiitis, alveolar proteinosis, alveolitis, al veolitis allergic, alveolitis necrotising, 
bronchiolitis, organising pneumonia, diffuse alveolar damage, diffu se panbronchiolitis, 
eosinophilic pneumonia, eosinophilic pneumoni a acute, eosinophilic pneumonia chronic, 
idiopathic pneumonia syndrome, idiopathic pu lmonary fibrosis, inte rstitial lung disease, 
loeffler’s syndrome, lower respiratory tract inflammation, lung induration, lung 
infiltration, acute lung injury, necrotisin g bronchiolitis, oblite rative bronchiolitis, 
pneumonitis, progressive massive fibrosis, pul monary eosinophilia, pulmonary fibrosis, 
pulmonary necrosis, pulmonary toxicity, pul monary alveolar haemorrhage, pulmonary 
haemorrhage, and non-cardiogenic pulmonary oedema. 
Method 
The incidence will be presented. 
6.1.2.6.  Reactivation of Hepatitis B  
Definition 
Reactivation of Hepatitis B includes adverse events in the following preferred terms: 
Hepatitis B, Acute hepatitis B, Hepatitis acute, Asymptomatic viral hepatitis, Chronic 
hepatitis B, Hepatitis post tr ansfusion, Hepatitis Viral.  
JNJ-26866138 (VELCADE* [Bortezomib] for Injection) Statistical Analysis Plan LYM-3002 
 36Prophylactic use of anti-virals of hepatitis  B includes lamivudine, entecavir, entecavir 
monohydrate, thymalfasin, with pr ophylaxis checked in the CRF. 
Method 
The incidence will be presented. The incide nce of hepatitis B by prophylactic use of anti-
virals of hepatitis B will be tabulated. 
6.1.2.7. Acute Hypersensitivity 
Definition 
This endpoint refers to those adverse events coded to the following preferred terms:   
allergic oedema, anaphylact ic reaction, anaphylactic shock, anaphylactoid reaction, 
anaphylactoid shock, angioedema, circumoral oedema, drug hypersensitivity, eyelid 
oedema, face oedema, hypersensitivity, laryng eal oedema, laryngotracheal oedema, lip 
oedema, lip swelling, oedema mouth, periorbi tal oedema, small bowel angioedema, tongue 
oedema, type I hypersensitivity, type IV hype rsensitivity reaction, swelling face, infusion 
site urticaria, and urticaria. 
Method 
The incidence will be presented. Incidence of  study drug related treatment-emergent acute 
hypersensitivity adverse events will be ta bulated by study drugs. Li sting of treatment-
emergent acute hypersensitivity adverse events will be provided. 
6.1.2.8. Central Nervous System Disorders  
Definition 
This endpoint refers to those adverse even ts coded to the follo wing preferred terms: 
Leukoencephalopathy, Progressive multifocal leukoencephalopathy, Posterior reversible 
encephalopathy syndrome, Guillain-Barre Syndrome, Encephalitis and Encephalopathy. 
Method 
The incidence will be presented. 6.1.2.9. Herpes Zoster Infection 
Definition 
This endpoint refers to thos e adverse events coded to th e following preferred terms:  
Encephalitis herpes, Herpes zoster multi-derm atomal, Herpes ophthalmic, Herpes zoster 
ophthalmic, Herpes sepsis, Herpes zoster oticus , Herpes zoster, Keratitis herpetic, Herpes 
zoster disseminated, Meningitis herpes, Herpes zoster infection neurological, 
Meningoencephalitis herpetic. 
JNJ-26866138 (VELCADE* [Bortezomib] for Injection) Statistical Analysis Plan LYM-3002 
 37Prophylactic use of anti-virals of herpes zoster includes aciclovi r, valaciclovir, famciclovir, 
valaciclovir hydrochloride, aciclovir sodium, with prophylaxis checked in the CRF. 
Method 
The incidence will be presented. The incidence by prophylactic use of anti-virals of herpes 
zoster will be tabulated. 
6.1.2.10. Thrombocytope nic Bleeding Events 
Definition 
This endpoint refers to the adverse events with the following  preferred terms: 
Abdominal wall haematoma, Abdominal wa ll haemorrhage, Acute haemorrhagic 
conjunctivitis, Adrenal haematoma, Adrenal ha emorrhage, Anal haemorrhage, Anal ulcer 
haemorrhage, Application site haematoma, Application site haemorrhage, Basal ganglia 
haemorrhage, Bloody discharge, Brain stem h aematoma, Brain stem haemorrhage, Brain 
stem microhaemorrhage, Breast haematoma, Breast haemorrhage, Bronchial haemorrhage, Catheter site haematoma, Catheter site haem orrhage, Central nervous system haemorrhage, 
Cerebellar haematoma, Cerebellar haemorrh age, Cerebellar microha emorrhage, Cerebral 
haematoma, Cerebral haemorrhage, Cere bral microhaemorrhage, Cerebrovascular 
accident, Cervix haematoma uterine, Cervix haemorrhage uterine, Choroidal haematoma, 
Choroidal haemorrhage, Ciliary body haemorrhage, Colonic haematoma, Conjunctival 
haemorrhage, Corneal bleedi ng, Cystitis haemorrhagic, Duodenitis haemorrhagic, Ear 
haemorrhage, Enterocolitis haemorrhagic , Epistaxis, Exsanguination, Extradural 
haematoma, Extravasation blood, Eye h aemorrhage, Eyelid bleeding, Gastric 
haemorrhage, Gastroduodenal haemorrhage, Gastroduodenitis haemorrhagic, 
Gastrointestinal haemorrhage, Gastrointestinal ulcer haemorrhage, Genital haemorrhage, 
Gingival bleeding, Haemarthrosis, Haematemesis, Haematochezia, Haematocoele, 
Haematoma, Haematosalpinx, Haematotympanum, Haemoptysis, Haemorrhage, 
Haemorrhage intracranial, Haemorrhage urinary tract, Haemorrhagic anaemia, 
Haemorrhagic cerebral infarction, Haemorrhagic disorder, Haemorrhagic stroke, Intestinal 
haematoma, Intestinal haemorrhage, Intr acranial haematoma, Intracranial tumour 
haemorrhage, Intraocular haematoma, Intrav entricular haemorrhage, Iris haemorrhage, 
Lacrimal haemorrhage, Large intestinal haemor rhage, Large intestinal ulcer haemorrhage, 
Lower gastrointestinal haemorrhage, Melaen a, Meningorrhagia, Mesenteric haematoma, 
Mesenteric haemorrhage, Mouth haemorrhage, Ocular retrobulbar haemorrhage, 
Oesophageal haemorrhage, Oesophagitis haem orrhagic, Optic disc haemorrhage, Optic 
nerve sheath haemorrhage, Ovarian haematoma,  Ovarian haemorrhage, Pelvic haematoma, 
Pelvic haematoma obstetric, Pelvic haemorrhage, Penile haematoma, Penile haemorrhage, 
Perineal haematoma, Periorbital haematom a, Periorbital haemorrhage, Pituitary 
JNJ-26866138 (VELCADE* [Bortezomib] for Injection) Statistical Analysis Plan LYM-3002 
 38haemorrhage, Prostatic haemorrhage, Puta men haemorrhage, Renal haematoma, Renal 
haemorrhage, Retinal haemorrhage, Retinopa thy haemorrhagic, Scleral haemorrhage, 
Scrotal haematocoele, Scrotal haematoma, Sp ermatic cord haemorrhage, Spinal cord 
haemorrhage, Spinal epidural haemorrhage, Spinal haematoma, Subarachnoid 
haemorrhage, Subdural haematoma, Subdural  haemorrhage, Subretinal haematoma, 
Testicular haemorrhage, Thalamus haemorrh age, Traumatic intracranial haemorrhage, 
Ureteric haemorrhage, Urethral haemorrhage, Uterine haematoma, Uterine 
haemorrhage,Vaginal haematoma, Vaginal haem orrhage, Vitreous haematoma, Vitreous 
haemorrhage, Vulval haematoma, Vulval haemorrhage, rectal haemorrhage, intra-
abdominal haematoma, post procedural haem orrhage, pulmonary haemorrhage, pulmonary 
alveolar haemorrhage, conjunctival haemorrh age, upper gastrointestinal haemorrhage, 
haemorrhoidal haemorrhage. 
Method 
The incidence will be presented. To review thrombocytopenic bleeding AEs, all grade 3 or 
more bleeding events where bleeding wa s associated with grade 3 or above 
trombocytopenia  will be reviewed. The thro mbocyte counts prior to the bleeding event 
will be taken into consideration. The pl atelet transfusion during the cycle where 
thrombocytopenic bleeding AEs  took place will also be reviewed. These events will be 
reviewed by 2 different physicians (project physician and GMS-P) independently. 
6.1.2.11. Neutropenic Sepsis and Infections Events 
Definition 
This endpoint refers to the adverse events in the SOC of infecti ons and infestations. 
Method 
The incidence will be presented. To review ne utropenic infection/sepsis AEs,  Infection 
SOC will be taken as a starting point and all grade 3 and above infections will be taken into 
account if patients who have experienced grade 3 or above infection/sepsis has also grade 
3 or above neutropenia at the time of the in fection. The G-CSF use during the cycle where 
the neutropenic infection/sepsis took place wi ll also be reviewed. These events will be 
reviewed by 2 different physicians (proje ct physician and GMS- P) independently.  
6.1.3. Death 
A tabulation will be produced for all-cause mort ality within 30 days and 60 days after the 
first dose, within 30 days  of the last dose, as well as all deaths for all subjects treated. Cause 
of death will be summarized as well in this ta ble. In particular, fre quencies of deaths that 
are due to study treatment -related adverse events will also be reported. 
JNJ-26866138 (VELCADE* [Bortezomib] for Injection) Statistical Analysis Plan LYM-3002 
 396.2. Clinical Laboratory Tests 
Laboratory data of hematology a nd clinical chemistry up to 30 days after last dose or the 
end of treatment visit date, whichever is later,  will be reported in SI  units. Normal ranges 
from local laboratories used in  this study will be listed.  
Summary statistics (mean, standard deviation, medi an and range) will be calculated for the 
raw data and for their changes from baseline at each time point of assessment as well as 
for the changes from baselin e to the last value.  
Graphical displays of over-time summaries w ill be presented for the following hematology 
parameters:  hemoglobin, neutr ophils, lymphocytes, platelets. 
Shift tables for each cycle will be produced fo r neutrophils and platelet s.  These tables will 
summarize by cycle the number of subjects with each baseline CTC grade and changes to 
the maximum CTC grade in the cycle.  
Changes from baseline to worst value on study (fr om treatment start to 30 days after last 
dose or the end of treatment visit date, whicheve r is later) will also be provided. The worst 
toxicity grade during the study will be tabulated. 
Due to the asymmetric assessment schedule between the two treatment groups for 
hematology laboratory tests, the shift tables and the summary of worst toxicity grade will 
be repeated excluding the samples taken on Days 4 and 8 of each cycle for those subjects 
treated with VcR-CAP. 
6.3. Vital Signs and Physi cal Examination Findings 
Over-time summary statistics (mean, standard deviation, median and ra nge) of vital signs 
will be provided. A separate summary will be produced for vital signs at baseline, 
maximum, change to maximum, last value, and change to last value. 
In addition, any signif icant vital sign changes will be tabulated.  Signif icant findings are 
defined as follows: 
 Systolic blood pressure:  changes of +/- 20%  or greater from ba seline (separately) 
 Diastolic blood pressure:  changes of +/- 20%  or greater from ba seline (separately) 
In order to be included in the table, a subj ect must have both a baseline value and a value 
for the given post-baseline time point. 
Abnormal physical examination findings will be tabulated by body system. 
JNJ-26866138 (VELCADE* [Bortezomib] for Injection) Statistical Analysis Plan LYM-3002 
 406.4. Electrocardiogram and ECHO/MUGA Scans 
A tabulation of ECG assessments will be made for the clinically significant changes in 
ECG evaluation during the study versus the baseli ne ECG assessment. Similar analysis will 
be done for ECHO/MUGA scans. 
7. PATIENT-REPORTED OU TCOMES (PRO) ENDPOINTS 
7.1. Definition 
Validated scoring algorithms will be used to derive the sc ores for the 3 PRO multi-item 
scales: 1) EORTC QLQ-C30 scales: one global s cale (global health status/quality of life), 
5 functional scales (physical functioning, role  functioning, emotional functioning, cognitive 
functioning, and social functioning), plus 3 symptom scales (fati gue, nausea and vomiting, 
and pain) and six single items (dyspnea, insomn ia, appetite loss, constip ation, diarrhea and 
financial difficulties)2) BFI (sever ity and fatigue); and 3) EQ-5D. 
7.2. Analysis Methods The number of available/missing assessments will be reported by scheduled visit and 
assessment/missing type.  
Absolute values of the EORTC QLQ-C30 and BFI scale scores (worst fatigue and 
interference scales) and changes from ba seline will be summarized (N, mean, SD, 
minimum, maximum) at each scheduled post-baseline assessment visit, along with graphs.  
For each of the scales in the EORTC QLQ-C30 and worst fatigue scale of the BFI, a 
repeated-measures model to estimate changes from baseline to post-baseline assessments 
will be conducted.  Treatment,  time, and the interaction between time and treatment will 
be included as discrete parameters. Serial co rrelation will be assumed using an unstructured 
covariance matrix to account for the correlati ons between all time points.  Change and 
corresponding standard error in each outcome measure on each time point up to Week 18 
will be estimated for each treatment group sepa rately and treatment and control will be 
compared. 
Graphics on EORTC QLQ-C30 and worst fatigue scale of the BFI will  be displayed with 
visits as the X-axis, and means (SEs) of EO RTC QLQ-C30 and worst fatigue scale of the 
BFI at each visit as the Y-axis. Cumulative distribution curves will be constr ucted for global health status in EORTC 
QLQ-C30 and worst fatigue scale of the BFI scales and displayed graphically.
 The curves 
will show a continuous plot of the absolute change of the last PRO measurement from baseline 
on the X-axis and the percent of subjects experiencing that change on the Y-axis for each of 
the treatment groups.  
JNJ-26866138 (VELCADE* [Bortezomib] for Injection) Statistical Analysis Plan LYM-3002 
 41Additional PRO Endpoints 
The EQ-5D assesses 5 dimensions (mobility, self care, usual activity, pain or discomfort, 
and anxiety or depression) of health relate d to PRO. Each dimension is measured on a 
3-point ordinal scale ranging between 1 (no li mitation) and 3 (greatest limitation) where a 
higher score corresponds to a worse health state. 
Responses in EQ-5D enable subjects to be as signed to 1 of 243 possi ble health states for 
which a global value (i.e., a "u tility score") is assigned. The utility score has been 
previously determined based on the prefer ences of a sample of 3,395 members of the 
United Kingdom general population. A utility score of 1 corres ponds to the highest degree 
of HRQOL, and score of 0 is compatible with a level of HRQOL equivalent to death. 
EQ-5D utility score 
Definition 
The EQ-5D utility scores will be computed using the UK value set obtained using Time 
Trade-Off (TTO) methodology from the table below. 
Value set for Calculation of the EQ-5D Scoring. 
UK TTO Value set 
 Weight 
Full Health (11111) 1 
At least one 2 or 3 (constant) -0.081 
At least one 3 -0.269 
Mobility = 2 -0.069 
Mobility = 3 -0.314 
Self care = 2 -0.104 
Self care = 3 -0.214 
Usual activities = 2 -0.036 
Usual activities = 3 -0.094 
Pain/Discomfort = 2 -0.123 
Pain/Discomfort = 3 -0.386 
Anxiety/Depression = 2 -0.071 
Anxiety/Depression = 3 -0.236 
 
For example, the EQ-5D utility sc ore for the health state 21232 is: 
Score 21232 = 1-0.081-0.269-0.069-0.036-0.386-0.071 = 0.088 
Analysis Methods 
Absolute values of the utility score for each of the 5 dimensions of EQ-5D, VAS, and their 
changes from baseline will be summarized at e ach scheduled post-baseline assessment visit 
(N, mean, SD, minimum, maximum).  Exploratory analysis will be performed when 
necessary. 
JNJ-26866138 (VELCADE* [Bortezomib] for Injection) Statistical Analysis Plan LYM-3002 
 428. BIOMARKER EVALUATIONS 
Biomarker analysis will be restricted to th e following two assessments based on results 
from previous studies [Coiffier 2013;  Goy 2010] (1) Pharmacogenomics and 
(2) Immunohistochemistry. The goal of the biom arker analysis is to provide some insight 
as to how subjects with certain prognostic markers (e.g. Ki67) respond to treatment or 
validate/confirm observations from previous studies that identified markers (e.g. PSMB) 
associated with better response to treatment.  
8.1. Definition 
Pharmacogenomic Analysis 
Genetic variability in drug target genes may influence drug binding and subsequently, 
response to treatment. Suspected drug ta rget genes for VELCADE, including 
PSMB1(P11A)  and PSMB5(R24C) , which are proteasome subunits  will be prospectively 
analyzed using whole blood DNA samples collecte d from consented subjects to determine 
any associations with response and PFS.  
Immunohistochemistry Analysis 
Paraffin-embedded, formalin-fixed tumor or fresh frozen tissue will be used for 
immunohistochemical analysis to quantify the ti ssue protein expression of the previously 
reported progonostic marker, Ki67. 
8.2.  Analysis Methods 
Pharmacogenomic Analysis 
The pharmacogenomic exploratory statistical anal ysis will be performed at the completion 
of the trial in order to inform subsequent  lymphoma trials.  Results from PSMB gene 
analysis will include investigation of associ ation of these genes w ith clinical endpoints 
including PFS and complete response. Analyses  will be performed within each treatment 
group and stratified by demographic and or base line features such as race, tumor burden, 
etc. Results of this prospective analysis will  be presented in a se parate report with key 
summary points included in the CSR.  
Immunohistochemistry Analysis 
The protein levels of Ki67 will be measured as scores on an  ordinal scale with a cut off 
10% as negative and >10% as positive. The im pact of protein expression level on response 
endpoints will be tested using standard categorical tests or survival analysis methods, as 
appropriate. Results of Ki67 analyses will be  presented in a separate report with key 
summary points included in the CSR.  
  
JNJ-26866138 (VELCADE* [Bortezomib] for Injection) Statistical Analysis Plan LYM-3002 
 43REFERENCES 
1. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin 
Oncol 2007; 25 (5):579-586. 
2. Coiffier B,  Henitz ED, Karkera J, et. al  Pre-specified candidate  biomarkers identify subjects with 
relapsed or refractory follicular lymphoma who achiev ed longer progression-free survival after treatment 
with bortezomib plus rituximab compared to rituximab alone. Under review 2013. 
3. Goy A, Bernstein SH, McDonald A, et al: Potential biomarkers of bortezomib activity in mantle cell 
lymphoma from the phase 2 PINNACLE trial. Leuk Lymphoma 2010; 51(7):1269-1277. 
  
JNJ-26866138 (VELCADE* [Bortezomib] for Injection) Statistical Analysis Plan LYM-3002 
 44ATTACHMENT 
Tumor Assessment Criteria (Modified IWRC) 
All tumor assessments will be done according to modified International Workshop to 
Standardize Response Criteria for non-H odgkin’s Lymphoma (IWRC) [Cheson 2007]). 
Relapsed disease is classified the same as PD  by IRC. The criteria that must be met for 
each disease response category, CR, CRu, PR, SD, disease re lapse and progression, are 
provided below. 
Complete Response (CR) requires ALL of the following: 
 Complete disappearance of all detectable clinical and radiological evidence of disease 
and disease-related symptoms and normalization of biochemical abnormalities 
definitely assignable to lymphoma (e .g., LDH) if present before therapy. 
 All measurable lymph nodes and nodal masse s must have regressed on CT to normal 
size (1.5 cm in their greatest transverse diamet er for nodes >1.5 cm before therapy).  
 Non-measurable and assessable nodes that were 1.1 to 1.5 cm in their greatest 
transverse diameter before trea tment must have decreased to 1 cm in their greatest 
transverse diameter after trea tment, or by more than 75% in the sum of the products of 
the greatest diameters (SPD), as visually estimated. 
 The spleen or liver, if considered enlarged  due to involvement with lymphoma before 
therapy on the basis of a physical examinati on or CT scan, should not be palpable on 
physical examination and should be cons idered normal size by imaging studies. 
Similarly, other organs considered to be en larged before therapy due to involvement 
by lymphoma such as kidneys, must have decreased in size. 
 If the bone marrow was involved by lymphom a, indeterminate or not adequately 
assessed during screening, an adequate aspira te and biopsy of the same site must be 
clear of lymphoma. 
 All extranodal sites of disease must have completely disappeared. 
Unconfirmed Complete Response (CRu) requires: 
That the first and fourth criter ia for CR be satisfied, however: 
 Any residual lymph node mass >1.5 cm in longe st transverse dimension or extranodal 
site of disease (irrespective of size) must  have regressed by more than 75% of the 
product of the longest perpendicular dimensions  compared to the pr etreatment baseline. 
 The bone marrow aspirate may be indetermin ate (contain increased number or size of 
lymphoid aggregates without cytolo gic or architectural atypia). 
 If there are residual masses in a subject w ho would otherwise be considered to have 
achieved a CR or CRu, the subject should be  classified as a partial responder. 
Partial Response (PR) requires ALL of the following: 
 At least a 50% decrease in sum of the product of the diameters (SPD ) of the measurable 
sites of disease.  
JNJ-26866138 (VELCADE* [Bortezomib] for Injection) Statistical Analysis Plan LYM-3002 
 45 No increase should be observed in  any site of disease that me et the criteria for relapsed 
or progressive disease.  
 Non-measurable nodes and nodules must regress by 50% in their SPD or, for single 
non-measurable lesions, in the greatest tran sverse diameter, as visually estimated. 
 Bone marrow assessment is irrelevant for determination of a PR if the sample was 
positive before treatment. However, subjec ts who achieve a CR by the above criteria, 
but who have persistent morphologic bone marrow involvement will be considered 
partial responders. When the bone marrow wa s involved before therapy and a clinical 
CR was achieved, but with no bone marrow asse ssment after treatment, subjects should 
be considered partial responders. 
 No new sites of disease should be observed that meet the criteri a for relapsed or 
progressive disease. 
Stable disease (SD) is defined as the following:  
 A subject is considered to have SD when he or she fails to attain the criteria needed for a CR or PR, but does not fulfill those for progressive disease (see below). 
Progressive Disease (after PR/SD) or Relapsed Disease (after CR/CRu) 
Progressive or relapsed disease re quires any one of the following: 
1. A) 50% increase from nadir in the SPD of a ll measurable sites of disease at the time 
that progressive or relapsed disease is iden tified and the absolute change in at least 1 
dimension is 0.5 cm for at least 1 lesion; or B) 50% increase in the long axis of any 
measurable site of disease at the time that prog ressive or relapsed disease is identified and 
the absolute change in the long axis is 0.5 cm. 
2. A) 50% increase from nadir in the SPD of  all non-measurable sites of disease 
(excluding truly assessable disease), as visually  estimated, and the absolute change in at 
least 1 dimension is 0.5 cm for at least 1 non-measured le sion as estimated visually; or B) 
50% increase in the long axis of any non-me asurable site of disease (excluding truly 
assessable disease), and the absolute change in the long axis is 0.5 cm, as estimated 
visually. 
3. 50% increase from nadir in any truly assessable site of disease, as visually estimated.  
4. Appearance of any new lymph node site of di sease that measures >1.5 cm in long axis 
and >1.0 cm in short axis, any new unequivocal extranodal site of disease (irrespective of 
size), or unequivocal evidence of a new site of assessable disease (for example effusions, 
ascites, masses with indistinct borders , new involvement of the bone marrow). 
5. Appearance of a new organ enlargement or unequivocal increase of an organ 
enlargement that was present since baseline. 
JNJ-26866138 (VELCADE* [Bortezomib] for Injection) Statistical Analysis Plan LYM-3002 
 46Measurable extranodal diseas e should be assessed in a ma nner similar to that for nodal 
disease. For these recommendations, the spleen is considered nodal disease. Disease that 
is only assessable (e.g., pleural effusions, bone  lesions) will be recorded as no change, 
increased, decreased, or new, unless, while an abnormality is still noted by imaging studies 
or physical examination, it is found to be histologically negative.  